AUS
NZ
UK
CA
USA
IND
Highlights
- Bio-Gene (BGT) opens Share Purchase Plan post $2.1M raise
- Eligible shareholders offered shares at $0.023 with bonus options
- Proceeds to support Flavocide®, Qcide® and regulatory initiatives
Bio-Gene Technology Limited (ASX:BGT), an Australian agtech innovator, has unveiled a Share Purchase Plan (SPP) to eligible shareholders following a successful $2.1 million capital raise through a placement to sophisticated and professional investors. The company is offering this SPP to provide existing shareholders an opportunity to participate in its ongoing capital strategy on equal footing.
Under the terms of the SPP, eligible shareholders—those holding shares as of 7:00 PM on May 2, 2025, with registered addresses in Australia—can subscribe for up to $15,000 worth of new shares at $0.023 each. This price matches the recent placement rate, ensuring parity between institutional and retail participants. One standout feature is the absence of brokerage or transaction fees, offering a streamlined process for participants.
Sweetening the Offer: Free-Attaching Options
In a value-added incentive, the company is offering free-attaching options. For every two shares acquired under the SPP, investors will receive one 2028 Option and one 2030 Option. These options are set with exercise prices of 3.4 cents and 4.6 cents, expiring on May 15, 2028, and May 15, 2030, respectively. The SPP opens on May 12, 2025, and closes at 7:00 PM on May 28, 2025.
Funding Key Innovations
Proceeds from both the placement and the SPP will be allocated toward the continued development of Bio-Gene’s novel insecticide technologies. Key areas of investment include regulatory studies for Flavocide®, scaling of Qcide®, formulation development, and advancing commercial partnerships. Funds will also support general working capital and costs tied to the capital raise.
CEO Tim Grogan commented that the positive response to the placement highlights growing confidence in the company's mission to bring next-generation pest control solutions to market. He emphasized that the capital raised will directly support the company's first regulatory submission for Flavocide® in Australia.
Investor Insights in a Broader Context
This move from Bio-Gene comes at a time when investor interest in growth-stage biotechnology and sustainability-focused enterprises is expanding, especially amid dynamic shifts within the ASX200 index landscape. While traditionally more mature firms are sought after for income—such as ASX dividend stocks—emerging innovators like Bio-Gene (BGT) are gaining attention for their long-term disruption potential.
